Cargando…
Potential treatment options and future research to increase hepatitis C virus treatment response rate
Hepatitis C virus (HCV) is a liver-tropic blood-borne pathogen that affects more than 170 million people worldwide. Although acute infections are usually asymptomatic, up to 90% of HCV infections persist with the possibility of long-term consequences such as liver fibrosis, cirrhosis, steatosis, ins...
Autores principales: | TenCate, Veronica, Sainz, Bruno, Cotler, Scott J, Uprichard, Susan L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039485/ https://www.ncbi.nlm.nih.gov/pubmed/21331152 http://dx.doi.org/10.2147/HMER.S7193 |
Ejemplares similares
-
Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection
por: Sainz, Bruno, et al.
Publicado: (2009) -
Hepatitis C Virus Infection in Phenotypically Distinct Huh7 Cell Lines
por: Sainz, Bruno, et al.
Publicado: (2009) -
Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies
por: Malespin, Miguel, et al.
Publicado: (2016) -
Developmental Regulation of Hepatitis B Virus Biosynthesis by Hepatocyte Nuclear Factor 4α
por: Li, Lie, et al.
Publicado: (2009) -
Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection
por: Canini, Laetitia, et al.
Publicado: (2017)